Acelyrin Insider Sellers Miss The Bus As Stock Jumps 13%

Although Acelyrin, Inc. (NASDAQ:SLRN) shareholders have enjoyed a great week with the stock up 13%, insiders who sold stock over the past year haven't fared as well. The return on their investment wo

Simply Wall StJun 12 08:09 ET

Express News | ACELYRIN, Inc. Announces Positive 16-Week Data From Its Global Phase 2B/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at Eular 2024

ReutersJun 5 07:00 ET

Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $68

Piper Sandler analyst Yasmeen Rahimi maintains $Acelyrin(SLRN.US)$ with a buy rating, and maintains the target price at $68.According to TipRanks data, the analyst has a success rate of 34.3% and a to

moomoo NewsMay 24 07:33 ET

Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Arrowhead Pharmaceuticals (ARWR) and NovoCure (NVCR)

TipRanksMay 24 06:50 ET

H.C. Wainwright Maintains Acelyrin(SLRN.US) With Buy Rating, Raises Target Price to $18

H.C. Wainwright analyst Emily Bodnar maintains $Acelyrin(SLRN.US)$ with a buy rating, and adjusts the target price from $16 to $18.According to TipRanks data, the analyst has a success rate of 37.3% a

moomoo NewsMay 23 06:32 ET

Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)

TipRanksMay 22 06:20 ET